Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial (2022)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1161/CIRCULATIONAHA.121.058103
- Subjects: HIPERTENSÃO; INSUFICIÊNCIA CARDÍACA; DIABETES MELLITUS; RESULTADO DE TRATAMENTO; FÁRMACOS (SISTEMA CARDIOVASCULAR)
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Philadelphia
- Date published: 2022
- Source:
- Título: Circulation
- ISSN: 0009-7322
- Volume/Número/Paginação/Ano: v. 145, n. 21, p. 1581-1591, 2022
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
-
ABNT
FURTADO, Remo H. M. et al. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation, v. 145, n. 21, p. 1581-1591, 2022Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.121.058103. Acesso em: 09 jan. 2026. -
APA
Furtado, R. H. M., Raz, I., Goodrich, E. L., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2022). Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation, 145( 21), 1581-1591. doi:10.1161/CIRCULATIONAHA.121.058103 -
NLM
Furtado RHM, Raz I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, Mcguire DK, Wilding JPH, Aylward P, Dalby AJ, Nicolau JC. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial [Internet]. Circulation. 2022 ; 145( 21): 1581-1591.[citado 2026 jan. 09 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.121.058103 -
Vancouver
Furtado RHM, Raz I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, Mcguire DK, Wilding JPH, Aylward P, Dalby AJ, Nicolau JC. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial [Internet]. Circulation. 2022 ; 145( 21): 1581-1591.[citado 2026 jan. 09 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.121.058103 - Oclusão de comunicação interventricular pós-infarto com prótese percutânea CERA
- Spontaneous MI After Non–ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial
- Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease
- Timing, Profile, and Predictors of Spontaneous Myocardial Infarction Following a Non-ST-Segment Elevation Acute Coronary Syndrome Event: Insights From the TRILOGY-ACS Trial
- The Efficacy and Safety of Low-Dose Rivaroxaban With or Without a Proton Pump Inhibitor: Insights From the ATLAS ACS 2-TIMI 51 Trial
- Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial
- Reduction in aubtypes and sizes of myocardial infarction with ticagrelor in PEGASUS-TIMI 54
- Left ventricular hypertrophy and QTc dispersion are predictors of long-term mortality in subjects with type 2 diabetes
- P2Y12 inhibitor switching in response to routine notification of CYP2C19 clopidogrel metabolizer status following acute coronary syndromes
- Extent of coronary and myocardial disease and benefit from surgical revascularization in LV dysfunction
Informações sobre o DOI: 10.1161/CIRCULATIONAHA.121.058103 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
